Drug-Drug Interaction Study of Evobrutinib and Transporter Substrates : A Phase I, Open-Label, Two-Part Study of the Effect of Multiple-Dose Evobrutinib on Transporter Substrates Digoxin, Metformin, Rosuvastatin, and Sumatriptan Pharmacokinetics in Healthy Participants
This study consists of 2 parts: Part 1 and 2. The purpose of this study is to evaluate the pharmacokinetic, safety and tolerability of multiple doses of evobrutinib on single doses of digoxin, metformin and rosuvastatin in Part-1 and sumatriptan in Part-2 of the study..
| Medienart: |
|
|---|
Klinische Studie| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
ClinicalTrials.gov - (2022) vom: 11. Jan. Zur Gesamtaufnahme - year:2022 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
610 |
|---|
| Anmerkungen: |
Source: Link to the current ClinicalTrials.gov record., First posted: October 1, 2021, Last downloaded: ClinicalTrials.gov processed this data on January 24, 2022, Last updated: January 26, 2022 |
|---|
| Study ID: |
NCT05064488 |
|---|---|
| Veröffentlichungen zur Studie: |
|
| fisyears: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
CTG007920156 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | CTG007920156 | ||
| 003 | DE-627 | ||
| 005 | 20230425210330.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 211006s2022 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)CTG007920156 | ||
| 035 | |a (UBBS_Klinische_Studien)NCT05064488 | ||
| 035 | |a (UBBS_Klinische_Studien)MS200527_0078 | ||
| 035 | |a (UBBS_Klinische_Studien)2021-001923-42 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Drug-Drug Interaction Study of Evobrutinib and Transporter Substrates |b A Phase I, Open-Label, Two-Part Study of the Effect of Multiple-Dose Evobrutinib on Transporter Substrates Digoxin, Metformin, Rosuvastatin, and Sumatriptan Pharmacokinetics in Healthy Participants |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: Link to the current ClinicalTrials.gov record., First posted: October 1, 2021, Last downloaded: ClinicalTrials.gov processed this data on January 24, 2022, Last updated: January 26, 2022 | ||
| 520 | |a This study consists of 2 parts: Part 1 and 2. The purpose of this study is to evaluate the pharmacokinetic, safety and tolerability of multiple doses of evobrutinib on single doses of digoxin, metformin and rosuvastatin in Part-1 and sumatriptan in Part-2 of the study. | ||
| 650 | 4 | |a Medical Condition: Healthy | |
| 650 | 4 | |a Study Type: Interventional | |
| 650 | 4 | |a Recruitment Status: Completed | |
| 650 | 4 | |a Phase: Phase 1 | |
| 650 | 4 | |a 610 | |
| 773 | 0 | 8 | |i Enthalten in |t ClinicalTrials.gov |g (2022) vom: 11. Jan. |
| 773 | 1 | 8 | |g year:2022 |g day:11 |g month:01 |
| 856 | 4 | 0 | |u https://clinicaltrials.gov/show/NCT05064488 |z kostenfrei |3 Volltext |
| 912 | |a GBV_CTG | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2022 |b 11 |c 01 | ||